Q2 FY2026 EarningsQ2 FY26 results significantly exceeded consensus expectations, driven by a $100M development milestone from AbbVie. Revenue reached $108.0M vs. the $96.5M expected, while Diluted EPS (GAAP) turned positive at $0.43 compared to the $0.015 mean estimate. Operational progress was robust, with the RGX-202 BLA submission on track for Q3 2026 and a July capital raise extending the cash runway into Q4 2027.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Regenxbio(RGNX) the Revenue is 108.02 M (+405.7%), Beat estimate;the EBIT is 29.26 M (+146.3%), Beat estimate;the EPS is 0.43 (+131.2%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.11B405.73%
0.10B351.60%
+0.01B54.13%
EBITExceed expectations
0.03B146.25%
0.01B118.11%
+0.02B28.14%
EPSExceed expectations
0.43131.16%
0.015101.09%
+0.415030.07%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf